Case Number:

IPR2019-00740

Case Type:

IPR

Status:

Terminated

Petitioner:

Amgen Inc.

Patent Owner:

Alexion Pharmaceuticals, Inc.

Tech Center:

1600

1. Filed: February 28, 2019 00:00

   Coverage

   1. June 02, 2020

      Amgen Drops Alexion Blood Drug IPRs, Gets 2025 License

      Amgen has agreed to drop three challenges to patents covering Alexion's blockbuster blood disorder treatment Soliris in exchange for a license that would let it make and sell a biosimilar version two years before the patents expire.

   ---

   Stay ahead of the curve

   In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.

   
   

   • Search PTAB cases and full-text documents.
   • Download filings with the U.S. Patent & Trademark Office’s Patent Trial & Appeal Board.
   • Set up alerts on new cases, follow ongoing cases, track new decisions and so much more!

   TRY LAW360 FREE FOR SEVEN DAYS

   View the PTAB case documents

   Already a subscriber? Click here to login